First line treatment of metastatic renal cell carcinoma: Two standards with different toxicity profile

Research output: Contribution to journalArticle

Abstract

Tyrosine kinase inhibitors are de facto the more used targeted therapies for upfront treatment of metastatic renal cell carcinoma (mRCC). Among these, sunitinib and pazopanib have reported greater activity in term of progression-free survival and overall survival compared with interferon-α or placebo in two independent large phase III studies. Despite a large use in clinical practice these molecules had never been compared. The COMPARZ study recently published in the New England Journal of Medicine reports the results of a non-inferiority trial that comparing pazopanib to sunitinib as first line of therapy in mRCC patients. Here we report the activity and safety data of the study and we discuss several critical aspects related to the study design and possible confounding factors that may alter the results' interpretation.

Original languageEnglish
Pages (from-to)19-21
Number of pages3
JournalCancer Biology and Therapy
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 2014

Keywords

  • First line
  • Non-inferiority study
  • Pazopanib
  • Phase III trial
  • Renal cancer
  • Sunitinib
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'First line treatment of metastatic renal cell carcinoma: Two standards with different toxicity profile'. Together they form a unique fingerprint.

  • Cite this